iRhythm vs Baxter International: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

iRhythm Technologies Inc (IRTC)

Q3 202616 Jul – 2 Oct 2026

▲2▼2

iRhythm raises guidance and settles lawsuit, but cyberattack and a slashed target weigh

Q2 beat and raised 2026 guidance iRhythm's second-quarter sales rose about 20% to $224 million, profit beat expectations, and the company lifted full-year 2026 revenue guidance to $880–$890 million. More sales and a better outlook make future profits look larger, which supports a higher stock price.
The raised guidance and earnings beat are the core new positive force on the stock.
$45 million settlement eases legal overhang iRhythm proposed a $45 million settlement of the securities class action over its Zio AT monitor disclosures. Putting a price on a long-running legal risk removes uncertainty that had been hanging over the stock, which investors generally treat as a plus.
The proposed settlement is a new event that reduces a known legal risk.
Cyberattack exposed patient data iRhythm said a June cyberattack accessed patient names, contact details, birth dates and insurance numbers, and it is notifying those affected. Even though the company says operations and finances are unaffected, a health-data breach can bring regulatory scrutiny and reputational damage, weighing on the stock.
The data breach is a new negative event with potential regulatory and reputational cost.
Truist's drastic price-target cut Truist cut its iRhythm price target to $18 from $160, a huge reduction that overshadowed the strong earnings and guidance raise. A big analyst target cut signals doubt about the company's value and can push the stock down even when results are good.
The sharp target cut is a new negative signal that offset the good earnings news.

August 202616 Jul – 2 Oct 2026

▲2▼2

iRhythm raises guidance and settles lawsuit, but cyberattack and a slashed target weigh

Q2 beat and raised 2026 guidance iRhythm's second-quarter sales rose about 20% to $224 million, profit beat expectations, and the company lifted full-year 2026 revenue guidance to $880–$890 million. More sales and a better outlook make future profits look larger, which supports a higher stock price.
The raised guidance and earnings beat are the core new positive force on the stock.
$45 million settlement eases legal overhang iRhythm proposed a $45 million settlement of the securities class action over its Zio AT monitor disclosures. Putting a price on a long-running legal risk removes uncertainty that had been hanging over the stock, which investors generally treat as a plus.
The proposed settlement is a new event that reduces a known legal risk.
Cyberattack exposed patient data iRhythm said a June cyberattack accessed patient names, contact details, birth dates and insurance numbers, and it is notifying those affected. Even though the company says operations and finances are unaffected, a health-data breach can bring regulatory scrutiny and reputational damage, weighing on the stock.
The data breach is a new negative event with potential regulatory and reputational cost.
Truist's drastic price-target cut Truist cut its iRhythm price target to $18 from $160, a huge reduction that overshadowed the strong earnings and guidance raise. A big analyst target cut signals doubt about the company's value and can push the stock down even when results are good.
The sharp target cut is a new negative signal that offset the good earnings news.

Latest16 Jul – 2 Oct 2026

▲2▼2

iRhythm raises guidance and settles lawsuit, but cyberattack and a slashed target weigh

Q2 beat and raised 2026 guidance iRhythm's second-quarter sales rose about 20% to $224 million, profit beat expectations, and the company lifted full-year 2026 revenue guidance to $880–$890 million. More sales and a better outlook make future profits look larger, which supports a higher stock price.
The raised guidance and earnings beat are the core new positive force on the stock.
$45 million settlement eases legal overhang iRhythm proposed a $45 million settlement of the securities class action over its Zio AT monitor disclosures. Putting a price on a long-running legal risk removes uncertainty that had been hanging over the stock, which investors generally treat as a plus.
The proposed settlement is a new event that reduces a known legal risk.
Cyberattack exposed patient data iRhythm said a June cyberattack accessed patient names, contact details, birth dates and insurance numbers, and it is notifying those affected. Even though the company says operations and finances are unaffected, a health-data breach can bring regulatory scrutiny and reputational damage, weighing on the stock.
The data breach is a new negative event with potential regulatory and reputational cost.
Truist's drastic price-target cut Truist cut its iRhythm price target to $18 from $160, a huge reduction that overshadowed the strong earnings and guidance raise. A big analyst target cut signals doubt about the company's value and can push the stock down even when results are good.
The sharp target cut is a new negative signal that offset the good earnings news.

Baxter International Inc (BAX)

Q3 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

August 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

Latest29 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.